Revakinagene for MacTel: Is the Benefit Worth the Cost? - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Revakinagene for MacTel: Is the Benefit Worth the Cost?

High-cost therapies have consistently been approved for conditions with significant unmet medical need, particularly when irreversible loss of function, such as blindness, is imminent. Decisions are based not only on clinical efficacy but also on prevention of long-term societal costs and preservation of patient autonomy. Therefore, it is our opinion that the benefit of revakinagene is worth the premium cost.

  • By

  • Michael Colucciello, MD

  • Martin Friedlander, MD, PhD

  • Kristin Raming, MD

  • September 1, 2026

  • 15 min

Share

Original Source(s)

Revakinagene for MacTel: Is the Benefit Worth the Cost?

  • by Michael Colucciello, MD, Martin Friedlander, MD, PhD, Kristin Raming, MD

  • September 1, 2026

Related Content

The Scleral Lens Vault: <br>Observing Your Fluorescein</br>

In the times of ever-advancing new technology for precise fitting of scleral lenses, has the art of diagnostic fitting fallen to the wayside

Procedural Pharmaceutical Lessons From Early Adopters

Experienced glaucoma surgeons share practical pearls on integrating sustained drug delivery into practice.

  • September 1, 2026

  • 18 min
Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.